FC
LSBPW

Finepoint Capital’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Finepoint Capital’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-489,999
Closed -$19.6K – 11
2025
Q2 		$19.6K Hold
489,999
– – ﹤0.01% 9
2025
Q1 		$20.2K Hold
489,999
– – ﹤0.01% 24
2024
Q4 		$48.5K Hold
489,999
– – ﹤0.01% 24
2024
Q3 		$24.2K Hold
489,999
– – ﹤0.01% 24
2024
Q2 		$33.4K Hold
489,999
– – 0.01% 21
2024
Q1 		$25K Hold
489,999
– – 0.01% 25
2023
Q4 		$13.3K Hold
489,999
– – ﹤0.01% 27
2023
Q3 		$17.1K Hold
489,999
– – 0.01% 27
2023
Q2 		$23K Hold
489,999
– – 0.01% 33
2023
Q1 		$76.3K Buy
+489,999
New +$74.2K 0.03% 25

Other funds holding LSBPW

HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Finepoint Capital's LSBPW Position: Q3 2025 in Review

Finepoint Capital sold out of LakeShore Biopharma Warrants (LSBPW) in Q3 2025, closing a stake of 489,999 shares — an estimated $19.6K sold.

Finepoint Capital first reported a position in LSBPW in Q1 2023 and held it in 10 quarters. The position peaked at $76.3K in Q1 2023. 3 funds tracked by Wall St. Rank hold LSBPW as of Q3 2025.

  • Finepoint Capital reported no remaining LakeShore Biopharma Warrants position as of Q3 2025 after selling out during the quarter.
  • Finepoint Capital sold 489,999 LakeShore Biopharma Warrants shares in Q3 2025, an estimated $19.6K.
  • Finepoint Capital first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 10 quarters.
  • Finepoint Capital's LakeShore Biopharma Warrants position peaked at $76.3K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q3 2025.

Based on Finepoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.